Committees

Cancer Immunotherapy Guidelines Myeloma Subcommittee

Cancer Immunotherapy Guidelines Non-Small Cell Lung Cancer (NSCLC) Subcommittee

Regulatory Subcommittee

International Committee

Science and Research Subcommittee

Early Career Scientist

Communications

Industry

Executive Council

Annual Program

Champions

Immune Biomarkers

Biomarker Data Sharing Subcommittee

Microbiome Subcommittee

Resources & Useful Tools Subcommittee

Tumor Mutational Burden Subcommittee

Cancer Immunotherapy Guidelines Renal Cell Carcinoma Subcommittee

Membership

Quality Subcommittee

Education and Training Committee

Advances in Cancer Immunotherapy™ (ACI) Committee

Forward Fund Committee

Cancer Immunotherapy Guidelines Acute Leukemia Subcommittee

Policy and Advocacy Committee

Bylaws

Advocacy Subcommittee

Cancer Immunotherapy Guidelines Committee

Publications

Cancer Immunotherapy Guidelines Lymphoma Subcommittee

Cancer Immunotherapy Guidelines Melanoma Subcommittee

Finance Committee

Cancer Immunotherapy Guidelines Bladder Carcinoma Subcommittee

Nominating Subcommittee

International Young Investigator Subcommittee

Cancer Immunotherapy Guidelines Prostate Carcinoma Subcommittee

Awards Review

Cancer Immunotherapy Guidelines Head and Neck Subcommittee

Immunoscore Steering Committee

Data Science and Big Data Task Force

PDL1 Resistance Definition Task Force

Surgery Committee

Cancer Immunotherapy Guidelines Immune-Checkpoint Inhibitors & Cytokines - Immune Related Adverse Ev

Cancer Immunotherapy Guidelines Immune Effector Cell - Immune Related Adverse Events Subcommittee

Clinical Demonstration Subcommittee

Global Regulation Subcommittee

Immunotherapeutic Infrastructure Subcommittee

International Education Subcommittee

Immunoscore Working Group

Data Sharing and Big Data Task Force

Global Access and Impact Committee

Anti-PD-1/PD-L1 Resistance Task Force